As Pharma Falters, Shire Specialist Model Hits Sweet Spot
This article was originally published in The Pink Sheet Daily
Executive Summary
With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.
You may also be interested in...
On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets
Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.
Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects
Collaboration will create start-up biotechs to advance promising research in orphan indications, but the companies will not take a “cookie cutter” approach to structure or evolution.
Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs